Drug Profile
Vorasidenib - Servier
Alternative Names: AG-881; AG-881 citrate; AGI-23088; S-95032; S095032; Vorasidenib citrateLatest Information Update: 26 Feb 2024
Price :
$50
*
At a glance
- Originator Agios Pharmaceuticals
- Developer Agios Pharmaceuticals; Servier
- Class Amines; Antineoplastics; Chlorinated hydrocarbons; Diamines; Fluorocarbons; Pyridines; Small molecules; Triazines
- Mechanism of Action Isocitrate dehydrogenase 1 inhibitors; Isocitrate dehydrogenase 2 inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Preregistration Glioma
- Phase I Astrocytoma; Liver disorders
- No development reported Haematological malignancies; Solid tumours
Most Recent Events
- 21 Feb 2024 Preregistration for Glioma (First-line therapy, In adolescents, In children, In the elderly, Recurrent, In adults) in European Union (PO)
- 21 Feb 2024 Preregistration for Glioma (First-line therapy, In adolescents, In children, In the elderly, Recurrent, In adults) in USA (PO)
- 20 Feb 2024 FDA assigns PDUFA action date of 20/08/2024 for vorasidenib for Glioma